Technology
Health
Biotechnology

Adverum Biotechnologies

$13.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.44 (-9.39%) As of 3:24 PM EDT today
-$1.44 (-9.39%) Today

Why Robinhood?

You can buy or sell ADVM and other stocks, options, ETFs, and crypto commission-free!

About ADVM

Adverum Biotechnologies, Inc. Common Stock, also called Adverum Biotechnologies, is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. Read More It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Employees
82
Headquarters
Menlo Park, California
Founded
2006
Market Cap
970.94M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.62M
High Today
$15.23
Low Today
$12.51
Open Price
$15.23
Volume
2.82M
52 Week High
$16.38
52 Week Low
$2.62

Collections

Technology
Health
Biotechnology
Medical
Gene Therapies
2016 IPO
US
North America

ADVM Earnings

-$0.34
-$0.30
-$0.27
-$0.23
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.